These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 39138277)

  • 1. Integrated transcriptomics- and structure-based drug repositioning identifies drugs with proteasome inhibitor properties.
    Larsson P; De Rosa MC; Righino B; Olsson M; Florea BI; Forssell-Aronsson E; Kovács A; Karlsson P; Helou K; Parris TZ
    Sci Rep; 2024 Aug; 14(1):18772. PubMed ID: 39138277
    [TBL] [Abstract][Full Text] [Related]  

  • 2.
    El Yaagoubi OM; Ezzemani W; Oularbi L; Samaki H; Aboudkhil S
    J Biomol Struct Dyn; 2024 Aug; 42(12):6165-6173. PubMed ID: 37403265
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Acute accumulation of PIM2 and NRF2 and recovery of β5 subunit activity mitigate multiple myeloma cell susceptibility to proteasome inhibitors.
    Sogabe K; Nakamura S; Higa Y; Miki H; Oda A; Maruhashi T; Sumitani R; Oura M; Takahashi M; Nakamura M; Maeda Y; Hara T; Yamagami H; Fujii S; Kagawa K; Ozaki S; Kurahashi K; Endo I; Aihara KI; Nakaue E; Hiasa M; Teramachi J; Harada T; Abe M
    Int J Hematol; 2024 Mar; 119(3):303-315. PubMed ID: 38245883
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cellular and computational studies of proteasome inhibition and apoptosis induction in human cancer cells by amino acid Schiff base-copper complexes.
    Zuo J; Bi C; Fan Y; Buac D; Nardon C; Daniel KG; Dou QP
    J Inorg Biochem; 2013 Jan; 118():83-93. PubMed ID: 23142973
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of the Proteasome β2 Site Sensitizes Triple-Negative Breast Cancer Cells to β5 Inhibitors and Suppresses Nrf1 Activation.
    Weyburne ES; Wilkins OM; Sha Z; Williams DA; Pletnev AA; de Bruin G; Overkleeft HS; Goldberg AL; Cole MD; Kisselev AF
    Cell Chem Biol; 2017 Feb; 24(2):218-230. PubMed ID: 28132893
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel aromatic sulfonyl naphthalene-based boronates as 20S proteasome inhibitors.
    Liu H; Wu J; Ge Y; Li A; Li J; Liu Z; Xu Y; Xu Q; Li Y
    Bioorg Med Chem; 2018 Mar; 26(5):1050-1061. PubMed ID: 29426629
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Proteasome Inhibition in Multiple Myeloma: Head-to-Head Comparison of Currently Available Proteasome Inhibitors.
    Besse A; Besse L; Kraus M; Mendez-Lopez M; Bader J; Xin BT; de Bruin G; Maurits E; Overkleeft HS; Driessen C
    Cell Chem Biol; 2019 Mar; 26(3):340-351.e3. PubMed ID: 30612952
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Discovery of a novel dipeptidyl boronic acid proteasome inhibitor for the treatment of multiple myeloma and triple-negative breast cancer.
    Lei M; Feng H; Bai E; Zhou H; Wang J; Qin Y; Zhang H; Wang X; Liu Z; Hai O; Liu J; Zhu Y
    Org Biomol Chem; 2019 Jan; 17(3):683-691. PubMed ID: 30601533
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Computational Approaches for the Discovery of Human Proteasome Inhibitors: An Overview.
    Guedes RA; Serra P; Salvador JA; Guedes RC
    Molecules; 2016 Jul; 21(7):. PubMed ID: 27438821
    [TBL] [Abstract][Full Text] [Related]  

  • 10. VR23: A Quinoline-Sulfonyl Hybrid Proteasome Inhibitor That Selectively Kills Cancer via Cyclin E-Mediated Centrosome Amplification.
    Pundir S; Vu HY; Solomon VR; McClure R; Lee H
    Cancer Res; 2015 Oct; 75(19):4164-75. PubMed ID: 26238784
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Discovering proteasomal deubiquitinating enzyme inhibitors for cancer therapy: lessons from rational design, nature and old drug reposition.
    Patel K; Ahmed ZS; Huang X; Yang Q; Ekinci E; Neslund-Dudas CM; Mitra B; Elnady FA; Ahn YH; Yang H; Liu J; Dou QP
    Future Med Chem; 2018 Sep; 10(17):2087-2108. PubMed ID: 30066579
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A High-Content Screening Assay for the Discovery of Novel Proteasome Inhibitors from Formosan Soft Corals.
    Ling XH; Wang SK; Huang YH; Huang MJ; Duh CY
    Mar Drugs; 2018 Oct; 16(10):. PubMed ID: 30347865
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Proteasome Inhibitors Bortezomib and Carfilzomib Stimulate the Transport Activity of Human Organic Anion Transporter 1.
    Fan Y; You G
    Mol Pharmacol; 2020 Jun; 97(6):384-391. PubMed ID: 32234809
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synthesis and mechanistic studies of quinolin-chlorobenzothioate derivatives with proteasome inhibitory activity in pancreatic cancer cell lines.
    Hu S; Jin Y; Liu Y; Ljungman M; Neamati N
    Eur J Med Chem; 2018 Oct; 158():884-895. PubMed ID: 30253345
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Multi-omics analysis identifies repurposing bortezomib in the treatment of kidney-, nervous system-, and hematological cancers.
    Larsson P; Olsson M; Sarathchandra S; Fäldt Beding A; Forssell-Aronsson E; Kovács A; Karlsson P; Helou K; Parris TZ
    Sci Rep; 2024 Aug; 14(1):18576. PubMed ID: 39127727
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combination of Second-Generation Proteasome Inhibitor Carfilzomib with Bortezomib in Four Different Breast Cancer Cell Lines.
    Altundag EM; Yilmaz AM; Sahin A; Yilmaz BK
    Anticancer Agents Med Chem; 2022 Aug; 22(16):2909-2918. PubMed ID: 35352669
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Discovery of a novel proteasome inhibitor selective for cancer cells over non-transformed cells.
    Kazi A; Lawrence H; Guida WC; McLaughlin ML; Springett GM; Berndt N; Yip RM; Sebti SM
    Cell Cycle; 2009 Jun; 8(12):1940-51. PubMed ID: 19471122
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification and in-vitro analysis of potential proteasome inhibitors targeting PSMβ5 for multiple myeloma.
    Yadav R; Nath UK; Celik I; Handu S; Jain N; Dhamija P
    Biomed Pharmacother; 2023 Jan; 157():113963. PubMed ID: 36399828
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Exocytosis of polyubiquitinated proteins in bortezomib-resistant leukemia cells: a role for MARCKS in acquired resistance to proteasome inhibitors.
    Franke NE; Kaspers GL; Assaraf YG; van Meerloo J; Niewerth D; Kessler FL; Poddighe PJ; Kole J; Smeets SJ; Ylstra B; Bi C; Chng WJ; Horton TM; Menezes RX; Musters RJ; Zweegman S; Jansen G; Cloos J
    Oncotarget; 2016 Nov; 7(46):74779-74796. PubMed ID: 27542283
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Activity patterns of proteasome subunits reflect bortezomib sensitivity of hematologic malignancies and are variable in primary human leukemia cells.
    Kraus M; Rückrich T; Reich M; Gogel J; Beck A; Kammer W; Berkers CR; Burg D; Overkleeft H; Ovaa H; Driessen C
    Leukemia; 2007 Jan; 21(1):84-92. PubMed ID: 17024115
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.